105 citations
,
December 1995 in “British journal of dermatology/British journal of dermatology, Supplement” This retrospective study concluded that PUVA treatment is generally ineffective for alopecia areata, with low effective success rates for partialis, totalis, and universalis types.
1 citations
,
January 2015 in “Acta Dermato Venereologica” Autoimmune myopathy may be linked to hair loss and skin depigmentation.
October 2021 in “Rheumatology Science and Practice” The article presents three clinical cases of universal alopecia developing during TNF-α inhibitor therapy and discusses possible mechanisms and the role of pro-inflammatory cytokines.
January 2021 in “Anais do Congresso Brasileiro de Reumatologia 2020” In this case report, tofacitinib led to significant improvement in arthritis and partial improvement in alopecia for a female patient with systemic lupus erythematosus, with no observed adverse effects.
Tofacitinib may effectively treat hair loss and improve symptoms in autoimmune conditions like alopecia areata and Sjögren's syndrome, but long-term treatment might be necessary.
16 citations
,
July 2017 in “Rheumatology and Therapy” This review examines the outcomes of treating Brazilian patients with alopecia universalis using tofacitinib and highlights the need for randomized controlled trials to determine optimal dosing and duration.
9 citations
,
November 2012 in “Hepatology Research” This case study reports the first instance of irreversible alopecia universalis occurring during pegylated interferon-ribavirin therapy in a man with hepatitis C infection, without evidence of immunological or thyroid disorders.
November 2023 in “Indian Dermatology Online Journal” This study found that tofacitinib was safe and effective for patients with severe or treatment-resistant alopecia areata, alopecia totalis, and alopecia universalis, resulting in significant hair regrowth for most participants.
87 citations
,
December 2016 in “British journal of dermatology/British journal of dermatology, Supplement” This study describes and characterizes four cases of alopecia areata induced by immune checkpoint inhibitor therapy in cancer patients, highlighting the importance of recognizing and managing these hair-related adverse events.
41 citations
,
August 2007 in “European Journal of Gastroenterology & Hepatology” This case report documents a reversible instance of complete body hair loss (alopecia universalis) in a patient undergoing chronic hepatitis C treatment with pegylated interferon alpha-2b and ribavirin, with hair regrowth observed within three months after therapy completion.
37 citations
,
October 2014 in “JAMA dermatology” This case report describes a woman with alopecia universalis, resistant to multiple treatments, who experienced successful hair regrowth with adalimumab, suggesting potential mechanisms for future investigation.
27 citations
,
April 2005 in “Journal of Chemotherapy” This study reported two cases of alopecia universalis triggered by PEG-interferon and ribavirin therapy for chronic hepatitis C, with hair regrowth observed after therapy completion or withdrawal.
18 citations
,
January 2013 in “PLoS ONE” This study identified several significant genetic variants associated with alopecia universalis, including a novel association with HLA-DRB5, which may play a hidden role in the disease.
4 citations
,
July 2005 in “International Journal of Dermatology” This article does not contain an abstract and presents no new clinical findings, instead discussing prior cases and literature on infant alopecia universalis and the potential role of topical PUVA therapy.
3 citations
,
July 2023 in “International Journal of Trichology” This study found that treatment with diphenylcyclopropenone led to more than 75% hair regrowth in 33.3% of patients with alopecia totalis or alopecia universalis, despite notable side effects.
2 citations
,
March 2022 in “Modern Rheumatology Case Reports” In this study, a case of a patient with dermatomyositis and alopecia universalis showed successful treatment with tofacitinib, suggesting potential responsiveness to janus kinase inhibitors.
1 citations
,
August 2022 in “Journal of Dermatology and Dermatologic Surgery” In this case report, tofacitinib was initiated in a 20-year-old female with alopecia universalis resistant to topical treatments, but resulted in a mild peripheral neuropathy side effect.
1 citations
,
July 2022 in “Bali Medical Journal” In this case report, treatment with corticosteroid and cyclosporine improved hair growth in a 19-year-old male with alopecia universalis over 51 days.
1 citations
,
November 2019 in “International Journal of Dermatology” This correspondence discusses the treatment of alopecia universalis in a 6-year-old girl using simvastatin/ezetimibe, minoxidil, and prednisolone, but it reports no new clinical findings.
July 2026 in “Journal of Investigative Dermatology” This retrospective cohort study found that individuals with alopecia totalis or universalis have a higher prevalence of systemic autoimmune diseases, particularly endocrine diseases and inflammatory bowel disease, compared to those with patchy alopecia areata.
July 2026 in “Journal of Investigative Dermatology” Alopecia totalis/universalis involves more intense immune activity and inflammation than patchy alopecia areata.
July 2025 in “International Journal of Homoeopathic Sciences” This case study reported significant hair regrowth and overall improvement in well-being for a male with Alopecia Universalis after receiving classical homeopathic treatment at Dr. Batra’s, suggesting potential long-term benefits from this intervention.
July 2025 in “Journal of Ayurveda Case Reports” This case report describes a five-year-old boy with Alopecia Universalis who did not respond to allopathic treatments but showed significant hair regrowth after two months of Ayurveda therapies, suggesting their potential effectiveness for this condition.
This case report highlights the growing prevalence and treatability of neurosyphilis, stressing the need to consider it in neurological symptoms such as encephalopathy, facial nerve palsy, and gelastic seizures associated with the frontal lobe.
September 2023 in “International Journal of Trichology” This case report describes a successful treatment of alopecia universalis in a 37-year-old female using oral tofacitinib, along with other therapies, resulting in significant hair regrowth without notable safety concerns.
May 2018 in “Journal of cosmetology & trichology” This study describes a case of successful treatment for alopecia universalis by combining PRP therapy with eye drops, resulting in significant hair regrowth and demonstrating no systemic side effects.
January 2017 in “DOAJ (DOAJ: Directory of Open Access Journals)” In this study, botulinum toxin type A did not improve clinical features in patients with recalcitrant alopecia totalis or alopecia universalis over a four-month period.
May 1979 in “Archives of Dermatology” This review discusses the associations between nonscarring alopecia and conditions like vitiligo and autoimmune reactions, but reports no new clinical results.
January 2022 in “Clinical, Cosmetic and Investigational Dermatology” This study reports promising results for alopecia universalis treatment using a combination of systemic methotrexate and low-dose corticosteroids with topical minoxidil, though monitoring for side effects is necessary.
39 citations
,
April 2003 in “Australasian journal of dermatology” This study found that PUVA treatment resulted in complete hair regrowth in over half of patients with alopecia areata totalis or universalis, despite a higher treatment failure rate in those with a family history of the condition.